However, our acceptances to both experimental and control group due to the paucity of available data, a lack of information on which disease phenotype of each participants belonged to and no uniformity of lifestyle intervention, GLP1RAs type or treatment duration, led to a moderate to high heterogeneity in some main outcomes
doi:10.1016/j.iac.2018.04.003 Sperr WR, Jordan JH, Fiegl M, et al
P53 phosphorylation at Ser15 enhances the affinity of both FOXO4 and FOXO4-DRI for p53 TAD2 explaining the preferential engagement of FOXO4-DRI with the hyperphosphorylated p53 characteristic of senescent cells
Last Reviewed: Q4 2025 Originally developed to treat Type 2 Diabetes, GLP-1s have since gained FDA approval for a variety of diseases, with new indications continually emerging
FAQ Can my doctor prescribe retatrutide